• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与失败的临床试验相关的因素及提高成功可能性的机会:一项综述。

Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review.

作者信息

Fogel David B

机构信息

Trials.ai, 4520 Executive Dr., Suite 200, San Diego, CA, 92121, United States.

出版信息

Contemp Clin Trials Commun. 2018 Aug 7;11:156-164. doi: 10.1016/j.conctc.2018.08.001. eCollection 2018 Sep.

DOI:10.1016/j.conctc.2018.08.001
PMID:30112460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6092479/
Abstract

Clinical trials are time consuming, expensive, and often burdensome on patients. Clinical trials can fail for many reasons. This survey reviews many of these reasons and offers insights on opportunities for improving the likelihood of creating and executing successful clinical trials. Literature from the past 30 years was reviewed for relevant data. Common patterns in reported successful trials are identified, including factors regarding the study site, study coordinator/investigator, and the effects on participating patients. Specific instances where artificial intelligence can help improve clinical trials are identified.

摘要

临床试验耗时、昂贵,且常常给患者带来负担。临床试验可能因多种原因失败。本调查回顾了其中许多原因,并就提高创建和执行成功临床试验可能性的机会提供见解。对过去30年的文献进行了回顾以获取相关数据。确定了已报告的成功试验中的常见模式,包括与研究地点、研究协调员/研究者相关的因素以及对参与患者的影响。确定了人工智能可以帮助改进临床试验的具体实例。

相似文献

1
Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review.与失败的临床试验相关的因素及提高成功可能性的机会:一项综述。
Contemp Clin Trials Commun. 2018 Aug 7;11:156-164. doi: 10.1016/j.conctc.2018.08.001. eCollection 2018 Sep.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Research Staff Perspectives on Cancer Clinical Trials and Barriers to Recruitment: A Qualitative Research.研究人员对癌症临床试验及招募障碍的看法:一项定性研究
Cureus. 2021 Aug 15;13(8):e17202. doi: 10.7759/cureus.17202. eCollection 2021 Aug.
5
Characteristics of successful recruitment in prospective pediatric pharmacogenetic studies.前瞻性儿科遗传药理学研究中成功招募的特点。
Clin Ther. 2011 Dec;33(12):2072-81. doi: 10.1016/j.clinthera.2011.10.026. Epub 2011 Dec 2.
6
Performance and predictors of recruitment success in National Heart, Lung, and Blood Institute's cardiovascular clinical trials.国家心肺血液研究所心血管临床试验中招募成功的表现和预测因素。
Clin Trials. 2018 Oct;15(5):444-451. doi: 10.1177/1740774518792271. Epub 2018 Aug 7.
7
Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study.随机试验的招募:试验入组与参与策略研究。STEPS研究。
Health Technol Assess. 2007 Nov;11(48):iii, ix-105. doi: 10.3310/hta11480.
8
Enrollment, retention, and strategies for including disadvantaged populations in randomized controlled trials: a systematic review protocol.纳入、保留和纳入随机对照试验中弱势群体的策略:系统评价方案。
Syst Rev. 2021 Aug 18;10(1):233. doi: 10.1186/s13643-021-01790-7.
9
Artificial Intelligence Applied to clinical trials: opportunities and challenges.人工智能应用于临床试验:机遇与挑战。
Health Technol (Berl). 2023;13(2):203-213. doi: 10.1007/s12553-023-00738-2. Epub 2023 Feb 28.
10

引用本文的文献

1
Nano-enabled strategies for targeted immunotherapy in gastrointestinal cancers.用于胃肠道癌症靶向免疫治疗的纳米技术策略
Front Immunol. 2025 Aug 14;16:1653829. doi: 10.3389/fimmu.2025.1653829. eCollection 2025.
2
Motivation, barriers, and willingness to participate in clinical trials for novel cancer treatments among the Vietnamese population.越南人群参与新型癌症治疗临床试验的动机、障碍及意愿
PLoS One. 2025 Aug 29;20(8):e0331250. doi: 10.1371/journal.pone.0331250. eCollection 2025.
3
ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory Biomarkers.脆性X综合征特异性临床试验中生物标志物组合的ROC分析:通过探索性生物标志物评估治疗效果。
Transl Psychiatry. 2025 Aug 28;15(1):323. doi: 10.1038/s41398-025-03558-2.
4
Drug repurposing in oncology: a path beyond the bottleneck.肿瘤学中的药物重新利用:突破瓶颈之路。
Med Oncol. 2025 Aug 24;42(10):443. doi: 10.1007/s12032-025-02994-w.
5
Insights From a User Experience-Focused Virtual Study on the Feasibility and Challenges of Decentralized Clinical Trials.一项以用户体验为重点的关于去中心化临床试验可行性和挑战的虚拟研究的见解
Clin Transl Sci. 2025 Aug;18(8):e70307. doi: 10.1111/cts.70307.
6
Effects of a non-standard information leaflet on patient recruitment in acute care: Embedded cluster-randomised controlled trial.非标准信息传单对急性护理中患者招募的影响:嵌入式整群随机对照试验。
PLoS One. 2025 Aug 1;20(8):e0327634. doi: 10.1371/journal.pone.0327634. eCollection 2025.
7
CLEAR: A vision to support clinical evidence lifecycle with continuous learning.清晰:通过持续学习支持临床证据生命周期的愿景。
J Biomed Inform. 2025 Jul 29;169:104884. doi: 10.1016/j.jbi.2025.104884.
8
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
9
Identification and Description of Regulatory and Health Technology Assessment Agencies' Guidance Related to Patient Experience Data in North America, Europe, and Asia Pacific.北美、欧洲和亚太地区监管机构及卫生技术评估机构与患者体验数据相关的指南识别与描述
Ther Innov Regul Sci. 2025 Jul 17. doi: 10.1007/s43441-025-00777-z.
10
Participant experiences in a decentralized clinical trial using digital health technologies: The ACTIV-6 study.使用数字健康技术的去中心化临床试验中的参与者体验:ACTIV-6研究。
J Clin Transl Sci. 2025 Apr 16;9(1):e121. doi: 10.1017/cts.2025.69. eCollection 2025.

本文引用的文献

1
The Life Cycle and Management of Protocol Deviations.方案偏离的生命周期与管理
Ther Innov Regul Sci. 2014 Nov;48(6):762-777. doi: 10.1177/2168479014530119.
2
Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy.用于胶质母细胞瘤的拓扑异构酶II抑制剂;个性化治疗的现有挑战与机遇
Front Neurol. 2018 Jun 20;9:459. doi: 10.3389/fneur.2018.00459. eCollection 2018.
3
Predicting enrollment performance of investigational centers in phase III multi-center clinical trials.预测Ⅲ期多中心临床试验中研究中心的入组表现。
Contemp Clin Trials Commun. 2017 Jul 20;7:208-216. doi: 10.1016/j.conctc.2017.07.004. eCollection 2017 Sep.
4
Associations between nurse education and experience and the risk of mortality and adverse events in acute care hospitals: A systematic review of observational studies.护士教育和经验与急性护理医院死亡率和不良事件风险之间的关联:观察性研究的系统评价。
Int J Nurs Stud. 2018 Apr;80:128-146. doi: 10.1016/j.ijnurstu.2018.01.007. Epub 2018 Jan 31.
5
Quality of inclusion criteria in the registered clinical trials of heart failure with preserved ejection fraction: Is it time for a change?射血分数保留的心力衰竭注册临床试验纳入标准的质量:是否是时候改变了?
Int J Cardiol. 2018 Mar 1;254:210-214. doi: 10.1016/j.ijcard.2017.12.025. Epub 2017 Dec 15.
6
Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎 3 期临床试验的成本驱动因素。
Clin Infect Dis. 2018 Jan 6;66(1):72-80. doi: 10.1093/cid/cix726.
7
Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype.个性化医疗中方法的成本效益。核型正常的急性髓系白血病患者决策分析模型的结果。
Leuk Res. 2017 Nov;62:84-90. doi: 10.1016/j.leukres.2017.09.009. Epub 2017 Sep 19.
8
Patient-reported tolerability of adverse events in phase 1 trials.患者报告的1期试验中不良事件的耐受性。
ESMO Open. 2017 Jun 23;2(2):e000148. doi: 10.1136/esmoopen-2016-000148. eCollection 2017.
9
Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results.改善临床研究中的选址:一种标准化、客观的多步骤方法及初步经验结果
BMJ Open. 2017 Jul 12;7(7):e014796. doi: 10.1136/bmjopen-2016-014796.
10
What trial participants need to be told about placebo effects to give informed consent: a survey to establish existing knowledge among patients with back pain.为了让试验参与者在知情同意的情况下了解安慰剂效应,他们需要知道什么:一项针对腰痛患者现有知识的调查。
J Med Ethics. 2017 Dec;43(12):867-870. doi: 10.1136/medethics-2016-103964. Epub 2017 Jun 29.